

Zoladex is indicated for the treatment of advanced prostate cancer, endometriosis, and hormone receptor-positive breast cancer in premenopausal women.

## **Clinical trials:**

### **Prostate Cancer Trials**

**Purpose:** Evaluate the efficacy and safety of goserelin in the treatment of prostate cancer, particularly in reducing tumor size and lowering prostate-specific antigen (PSA) levels.

**Dates:** Multiple trials conducted from the 1980s onwards.

**Results:** Clinical trials showed that goserelin was effective in reducing tumor size, alleviating symptoms, and lowering PSA levels in patients with prostate cancer. It also demonstrated a manageable side effect profile.

**Impact:** These trials supported the approval of Zoladex for the treatment of prostate cancer.

### **Breast Cancer Trials**

**Purpose:** Evaluate the role of goserelin in the treatment of premenopausal women with hormone receptor-positive breast cancer, either alone or in combination with other therapies.

**Dates:** Various trials conducted from the 1980s onwards.

**Results:** Clinical trials demonstrated that goserelin, when used in combination with other therapies or as adjuvant therapy, could improve outcomes in premenopausal women with hormone receptor-positive breast cancer. It also showed a favorable safety profile.

**Impact:** These trials supported the use of Zoladex in the treatment of hormone receptor-positive breast cancer in premenopausal women.